文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

ICU中米多君使用趋势:单中心回顾性病例系列

Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论单中心回顾性病例系列显示,ICU中米多君超说明书使用逐年增加,用药24小时后使用血管升压药的患者数及累积剂量下降,但可出现无症状性心动过缓与肠缺血。

该单中心回顾性病例系列纳入2011年1月至2016年10月Mayo Clinic Rochester成人ICU中因低血压接受米多君的患者共1119例(外科ICU 56%、内科ICU 42%、神经内科混合ICU 2%),无干预,比较用药前后平均动脉压与累积血管升压药剂量并记录并发症。用药24小时后使用血管升压药的患者数由663例降至344例(p<0.001),仍在用血管升压药者中位累积剂量显著下降(p=0.002),未用血管升压药者中位平均动脉压由65升至68(p<0.01)。无症状性心动过缓(心率<50次/分)最常见(172例,中位39次/分),2例发生肠缺血。作者认为米多君作为辅助升压和促进血管升压药撤离的使用在增加,需前瞻性试验确定时机、疗效、安全性和成本效益。

要点

  • 1119例ICU低血压患者启用米多君,外科ICU占56%、内科ICU占42%、神经内科混合ICU占2%。
  • 启用米多君24小时后使用血管升压药的患者数由663例降至344例(p<0.001)。
  • 仍在用血管升压药者中位累积血管升压药剂量显著下降(p=0.002)。
  • 未用血管升压药者中位平均动脉压由65升至68(p<0.01)。
  • 无症状性心动过缓(心率<50次/分)最常见(172例,中位39次/分),2例发生肠缺血。

适用人群与场景

  • 2011年1月至2016年10月Mayo Clinic Rochester内科和外科ICU的成人患者。
  • 纳入标准:入住任一ICU并因低血压接受米多君的成人患者。

红旗征与不能漏的情况

  • 无症状性心动过缓(心率<50次/分)为最常见副作用(172例,中位39次/分)。
  • 2例在启用米多君后发生肠缺血,其中1例因此停用米多君。

研究设计与关键结果

  • 研究类型:单中心回顾性病例系列,无干预,比较米多君给药前后平均动脉压与累积血管升压药剂量并评估报告的并发症。
  • 研究期间共1119例患者启用米多君,其中外科ICU 56%、内科ICU 42%、内科与外科混合神经内科ICU 2%。
  • 启用米多君24小时后使用血管升压药的患者数由663例降至344例(p<0.001)。
  • 仍在用血管升压药的患者中,中位累积血管升压药剂量显著下降(p=0.002)。
  • 未用血管升压药的患者中,启用米多君24小时后中位平均动脉压由65升至68(p<0.01)。
  • 无症状性心动过缓(心率<50次/分)为最常见副作用(172例,中位39次/分);2例发生肠缺血,其中1例停用米多君。
  • 趋势评估显示,米多君的超说明书使用在各ICU逐年稳步增加。

证据类型、等级与局限

  • 证据类型:单中心回顾性病例系列。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,米多君在ICU被越来越多地用作辅助升压和促进血管升压药撤离的手段。
  • 作者认为,需前瞻性试验进一步确定ICU患者使用米多君的适当时机、疗效、安全性和成本效益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution.

DESIGN: Single-center retrospective case series.

SETTING: Medical and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester.

PATIENTS: Adult patients admitted to any ICU who received midodrine for hypotension were eligible.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56% in surgical ICUs, 42% in medical ICUs, and 2% in a mixed medical and surgical neurology ICU. There was a significant decrease in the number of patients on vasopressors 24 hours after initiation of midodrine (663 to 344; p < 0.001); among the patients that remained on vasopressors, there was a significant decrease in the median cumulative vasopressor dose (p = 0.002). There was a significant increase in median mean arterial pressure 24 hours after initiation of midodrine among patients who were not on vasopressors (65-68; p < 0.01). Asymptomatic bradycardia (heart rate < 50 beats/min) was the most common side effect (n = 172 patients, median 39 beats/min). Two patients developed bowel ischemia after initiation of midodrine that prompted discontinuation of midodrine in one case. Evaluating trends of utilization, the off-label use of midodrine has increased steadily over the years across ICUs.

CONCLUSIONS: Our results suggest that midodrine is being increasingly used as an adjunct to increase mean arterial pressure and facilitate weaning of vasopressors in the ICU. Prospective trials are required to further establish the appropriate timing, efficacy, safety, and cost-effectiveness of midodrine use in ICU patients.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Rizvi MS, Trivedi V, Nasim F, et al. Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. Crit Care Med. 2018. PMID: 29613861. doi:10.1097/CCM.0000000000003121

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。